Skip to main content
Top
Published in: BMC Urology 1/2012

Open Access 01-12-2012 | Research article

Stage I seminoma: treatment outcome at King Hussein Cancer Center in Jordan

Authors: Jamal Khader, Ahmed Salem, Yazan Abuodeh, Abdelateif Almousa, Naim Farah, Fadwa Abdelrahman

Published in: BMC Urology | Issue 1/2012

Login to get access

Abstract

Background

The aim of this report is to address treatment outcomes of patients with early-stage seminoma in a single institution with special reference to patients with history of surgical violation of the scrotum.

Methods

Seventy four patients with pure seminoma were treated at King Hussein Cancer Center (Amman, Jordan) between 2003 and 2010. All patients underwent orchiectomy. All but 3 patients received adjuvant radiotherapy. Patients who underwent surgical violation of the scrotum prior to referral were managed by further excision or irradiation of the scrotal scar. The follow-up ranged from 1 to 200 months (mean, 33 months).

Results

At the time of follow-up; all but one patient remain alive. The 3-year relapse-free survival for the entire cohort was 95.9%. Three patients developed relapse, all of whom received adjuvant irradiation following inguinal orchiectomy and initially harbored tumors larger than 4 cm upon pathological examination. Median time to relapse was 14 months (range, 8–25 months). None were associated with elevated tumor markers prior to detection of relapse. All but one patient were successfully salvaged by chemotherapy.

Conclusions

Our results confirm the excellent prognosis of patients with early-stage seminoma treated by orchiectomy and adjuvant radiotherapy in a developing country. Although all patients who developed relapse demonstrated adverse pathological findings upon initial assessment, no consistent predictor of relapse was found. Scrotal scar re-excision or irradiation in patients with prior history of surgical violation of the scrotum are effective measures in preventing local failure.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alomary I, Samant R, Gallant V: Treatment of stage I seminoma: a 15-year review. Urol Oncol. 2006, 24 (3): 180-183. 10.1016/j.urolonc.2005.05.010.CrossRefPubMed Alomary I, Samant R, Gallant V: Treatment of stage I seminoma: a 15-year review. Urol Oncol. 2006, 24 (3): 180-183. 10.1016/j.urolonc.2005.05.010.CrossRefPubMed
2.
go back to reference Pectasides D, Pectasides E, Constantinidou A, Aravantinos G: Stage I testicular seminoma: management and controversies. Crit Rev Oncol Hematol. 2009, 71 (1): 22-28. 10.1016/j.critrevonc.2008.10.007.CrossRefPubMed Pectasides D, Pectasides E, Constantinidou A, Aravantinos G: Stage I testicular seminoma: management and controversies. Crit Rev Oncol Hematol. 2009, 71 (1): 22-28. 10.1016/j.critrevonc.2008.10.007.CrossRefPubMed
3.
go back to reference Yang GY, Li B, Wagner TD, Donohue KA, Flaherty L, Kuettel MR: Long-term outcome of stage I seminoma. Am J Clin Oncol. 2007, 30 (2): 205-210. 10.1097/01.coc.0000255613.72254.31.CrossRefPubMed Yang GY, Li B, Wagner TD, Donohue KA, Flaherty L, Kuettel MR: Long-term outcome of stage I seminoma. Am J Clin Oncol. 2007, 30 (2): 205-210. 10.1097/01.coc.0000255613.72254.31.CrossRefPubMed
4.
go back to reference Kamba T, Kamoto T, Okubo K, et al: Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol. 2010, 17 (12): 980-987. 10.1111/j.1442-2042.2010.02645.x.CrossRefPubMedPubMedCentral Kamba T, Kamoto T, Okubo K, et al: Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol. 2010, 17 (12): 980-987. 10.1111/j.1442-2042.2010.02645.x.CrossRefPubMedPubMedCentral
5.
go back to reference Chung P, Warde P: Stage I seminoma: adjuvant treatment is effective but is it necessary?. J Natl Cancer Inst. 2011, 103 (3): 194-196. 10.1093/jnci/djq535.CrossRefPubMed Chung P, Warde P: Stage I seminoma: adjuvant treatment is effective but is it necessary?. J Natl Cancer Inst. 2011, 103 (3): 194-196. 10.1093/jnci/djq535.CrossRefPubMed
6.
go back to reference Sobin LH, Wittekind C: TNM Classification of Malignant Tumours. 2002, John Wiley & Sons, Hoboken, New Jersey, 199-202. 6 Sobin LH, Wittekind C: TNM Classification of Malignant Tumours. 2002, John Wiley & Sons, Hoboken, New Jersey, 199-202. 6
7.
go back to reference Fosså SD, Horwich A, Russell JM, et al: Optimal radiotherapy field size for stage I testicular seminoma: a Medical Research Council (UK) randomised trial. J Clin Oncol. 1999, 17 (4): 1146-1154.PubMed Fosså SD, Horwich A, Russell JM, et al: Optimal radiotherapy field size for stage I testicular seminoma: a Medical Research Council (UK) randomised trial. J Clin Oncol. 1999, 17 (4): 1146-1154.PubMed
8.
go back to reference Tarawneh M, Nimri O, Arqoub K, Zaghal M: Jordan Cancer Registry: Cancer incidence in Jordan 2008. 2008, Ministry of Health, Non-Communicable Diseases Directorate Tarawneh M, Nimri O, Arqoub K, Zaghal M: Jordan Cancer Registry: Cancer incidence in Jordan 2008. 2008, Ministry of Health, Non-Communicable Diseases Directorate
9.
go back to reference Bissada NK, el Senoussi M, Hanash KA, Hefty T, Morcos R: Testicular seminomas in Saudi Arabia: clinical characteristics, prognostic indicators, and recommendations for management. J Surg Oncol. 1986, 33 (2): 136-139. 10.1002/jso.2930330218.CrossRefPubMed Bissada NK, el Senoussi M, Hanash KA, Hefty T, Morcos R: Testicular seminomas in Saudi Arabia: clinical characteristics, prognostic indicators, and recommendations for management. J Surg Oncol. 1986, 33 (2): 136-139. 10.1002/jso.2930330218.CrossRefPubMed
10.
go back to reference Mok G, Warde P: Management of stage I testicular seminoma. Hematol Oncol Clin North Am. 2011, 25 (3): 503-516. 10.1016/j.hoc.2011.03.008. vii-iiiCrossRefPubMed Mok G, Warde P: Management of stage I testicular seminoma. Hematol Oncol Clin North Am. 2011, 25 (3): 503-516. 10.1016/j.hoc.2011.03.008. vii-iiiCrossRefPubMed
11.
go back to reference Schmoll HJ, Jordan K, Huddart R, et al: Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009, 20 (Suppl 4): 83-88.PubMed Schmoll HJ, Jordan K, Huddart R, et al: Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009, 20 (Suppl 4): 83-88.PubMed
12.
go back to reference Clasen J, Schmidberger H, Souchon R, et al: What is the value of routine follow-up in stage I seminoma after paraaortic radiotherapy?: an analysis of the German Testicular Cancer Study Group (GTCSG) in 675 prospectively followed patients. Strahlenther Onkol. 2009, 185 (6): 349-354. 10.1007/s00066-009-1958-z.CrossRefPubMed Clasen J, Schmidberger H, Souchon R, et al: What is the value of routine follow-up in stage I seminoma after paraaortic radiotherapy?: an analysis of the German Testicular Cancer Study Group (GTCSG) in 675 prospectively followed patients. Strahlenther Onkol. 2009, 185 (6): 349-354. 10.1007/s00066-009-1958-z.CrossRefPubMed
13.
go back to reference Niewald M, Freyd J, Fleckenstein J, Wullich B, Rübe C: Low-dose radiotherapy for Stage I seminoma–long-term results. Int J Radiat Oncol Biol Phys. 2006, 66 (4): 1112-1119. 10.1016/j.ijrobp.2006.06.054.CrossRefPubMed Niewald M, Freyd J, Fleckenstein J, Wullich B, Rübe C: Low-dose radiotherapy for Stage I seminoma–long-term results. Int J Radiat Oncol Biol Phys. 2006, 66 (4): 1112-1119. 10.1016/j.ijrobp.2006.06.054.CrossRefPubMed
14.
go back to reference Jones WG, Fossa SD, Mead GM, et al: A randomised trial of 30 Gy vs 20 Gy in the adjuvant treatment of stage I testicular seminoma (MRC TE18, EORTC 30942, ISRCTN18525328). J Clin Oncol. 2005, 23 (6): 1200-1208. 10.1200/JCO.2005.08.003.CrossRefPubMed Jones WG, Fossa SD, Mead GM, et al: A randomised trial of 30 Gy vs 20 Gy in the adjuvant treatment of stage I testicular seminoma (MRC TE18, EORTC 30942, ISRCTN18525328). J Clin Oncol. 2005, 23 (6): 1200-1208. 10.1200/JCO.2005.08.003.CrossRefPubMed
15.
go back to reference Sultanem K, Souhami L, Benk V, et al: Para-aortic irradiation only appears to be adequate treatment for patients with Stage I seminoma of the testis. Int J Radiat Oncol Biol Phys. 1998, 40 (2): 455-459. 10.1016/S0360-3016(97)00733-5.CrossRefPubMed Sultanem K, Souhami L, Benk V, et al: Para-aortic irradiation only appears to be adequate treatment for patients with Stage I seminoma of the testis. Int J Radiat Oncol Biol Phys. 1998, 40 (2): 455-459. 10.1016/S0360-3016(97)00733-5.CrossRefPubMed
16.
go back to reference Power RE, Kennedy J, Crown J, Fraser I, Thornhill JA: Pelvic recurrence in stage I seminoma: a new phenomenon that questions modern protocols for radiotherapy and follow-up. Int J Urol. 2005, 12 (4): 378-382. 10.1111/j.1442-2042.2005.01114.x.CrossRefPubMed Power RE, Kennedy J, Crown J, Fraser I, Thornhill JA: Pelvic recurrence in stage I seminoma: a new phenomenon that questions modern protocols for radiotherapy and follow-up. Int J Urol. 2005, 12 (4): 378-382. 10.1111/j.1442-2042.2005.01114.x.CrossRefPubMed
17.
go back to reference Travis L, Curtis R, Storm H, et al: Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997, 89: 1429-1439. 10.1093/jnci/89.19.1429.CrossRefPubMed Travis L, Curtis R, Storm H, et al: Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997, 89: 1429-1439. 10.1093/jnci/89.19.1429.CrossRefPubMed
18.
go back to reference Stein ME, Leviov M, Drumea K, et al: Radiation-induced tumors in irradiated stage I testicular seminoma: results of a 25-year follow-up (1968–1993). J Surg Oncol. 1998, 67 (1): 38-40. 10.1002/(SICI)1096-9098(199801)67:1<38::AID-JSO8>3.0.CO;2-N.CrossRefPubMed Stein ME, Leviov M, Drumea K, et al: Radiation-induced tumors in irradiated stage I testicular seminoma: results of a 25-year follow-up (1968–1993). J Surg Oncol. 1998, 67 (1): 38-40. 10.1002/(SICI)1096-9098(199801)67:1<38::AID-JSO8>3.0.CO;2-N.CrossRefPubMed
19.
go back to reference Oliver RTD, Mason MD, Mead GM, et al: for the MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005, 366 (9482): 293-300. 10.1016/S0140-6736(05)66984-X.CrossRefPubMed Oliver RTD, Mason MD, Mead GM, et al: for the MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005, 366 (9482): 293-300. 10.1016/S0140-6736(05)66984-X.CrossRefPubMed
20.
go back to reference Warde P, Specht L, Horwich A, et al: Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002, 20: 4448-4452. 10.1200/JCO.2002.01.038.CrossRefPubMed Warde P, Specht L, Horwich A, et al: Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002, 20: 4448-4452. 10.1200/JCO.2002.01.038.CrossRefPubMed
21.
go back to reference Jones RH, Vasey PA: Part I: testicular cancer-management of early disease. Lancet Oncol. 2003, 4: 730-736. 10.1016/S1470-2045(03)01278-6.CrossRefPubMed Jones RH, Vasey PA: Part I: testicular cancer-management of early disease. Lancet Oncol. 2003, 4: 730-736. 10.1016/S1470-2045(03)01278-6.CrossRefPubMed
22.
go back to reference Horwich A: Radiotherapy in stage I seminoma of testis. J Clin Oncol. 2004, 22: 585-588. 10.1200/JCO.2004.12.966.CrossRefPubMed Horwich A: Radiotherapy in stage I seminoma of testis. J Clin Oncol. 2004, 22: 585-588. 10.1200/JCO.2004.12.966.CrossRefPubMed
23.
go back to reference Martin J, Chung P, Warde P: Treatment options, prognostic factors and selection of treatment in stage I seminoma. Onkologie. 2006, 29 (12): 592-598. 10.1159/000096608.PubMed Martin J, Chung P, Warde P: Treatment options, prognostic factors and selection of treatment in stage I seminoma. Onkologie. 2006, 29 (12): 592-598. 10.1159/000096608.PubMed
24.
go back to reference Christoph F, Weikert S, Miller K, Schrader M: New guidelines for clinical stage I testicular seminoma?. Oncology. 2005, 69 (6): 455-462. 10.1159/000090493.CrossRefPubMed Christoph F, Weikert S, Miller K, Schrader M: New guidelines for clinical stage I testicular seminoma?. Oncology. 2005, 69 (6): 455-462. 10.1159/000090493.CrossRefPubMed
25.
go back to reference Francis R, Bower M, Brunstrom G, et al: Surveillance for stage I testicular germ cell tumors: results and cost benefit analysis of management options. Eur J Cancer. 2000, 36: 1925-1932. 10.1016/S0959-8049(00)00140-4.CrossRefPubMed Francis R, Bower M, Brunstrom G, et al: Surveillance for stage I testicular germ cell tumors: results and cost benefit analysis of management options. Eur J Cancer. 2000, 36: 1925-1932. 10.1016/S0959-8049(00)00140-4.CrossRefPubMed
Metadata
Title
Stage I seminoma: treatment outcome at King Hussein Cancer Center in Jordan
Authors
Jamal Khader
Ahmed Salem
Yazan Abuodeh
Abdelateif Almousa
Naim Farah
Fadwa Abdelrahman
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2012
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-12-10

Other articles of this Issue 1/2012

BMC Urology 1/2012 Go to the issue